Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,714,080
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.68
  • Price/Sales 7.22
  • Price/Cash Flow 19.53
  • Price/Book 16.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.60 +11.68%
on 06/20/18
50.36 -1.09%
on 07/18/18
+5.14 (+11.51%)
since 06/19/18
3-Month
44.28 +12.50%
on 06/12/18
50.36 -1.09%
on 07/18/18
+2.15 (+4.51%)
since 04/19/18
52-Week
41.03 +21.40%
on 07/27/17
58.37 -14.67%
on 01/23/18
+7.24 (+17.01%)
since 07/19/17

Most Recent Stories

More News
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 49.81 (-0.82%)
LLY : 89.43 (-0.67%)
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 49.81 (-0.82%)
LLY : 89.43 (-0.67%)
The Shared Services and Outsourcing Network Presents Nordic Business Transformation: Nordic BT 2018 Is Transforming the Back-offices of the Future

Change or die is the message for the day, transformation will be the defining factor in the success of future businesses. Nordic Business Transformation 2018 (Nordic BT) aims to bring together experts...

NVO : 49.81 (-0.82%)
Pharmaceuticals for Women's Health: Global Markets to 2023 - ResearchAndMarkets.com

The "Pharmaceuticals for Women's Health: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering. While women's health encompasses several health issues,...

BAYRY : 26.9050 (-0.59%)
NVO : 49.81 (-0.82%)
JNJ : 125.94 (-1.46%)
AGN : 173.39 (-1.40%)
ABBV : 89.95 (-4.71%)
AMGN : 191.76 (-0.54%)
Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research

Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the appointment of Grant Blouse,...

NVO : 49.81 (-0.82%)
CBIO : 10.91 (-6.03%)
7th European Trial Master File Summit --- Europe's Premier TMF Event

Are you aware that the largest European TMF event -- ExL Events' 7th European Trial Master File Summit [https://goo.gl/LE3gJL] -- is taking place on 15-17 October 2018 at the Hilton London Bankside? This...

NVO : 49.81 (-0.82%)
GILD : 77.05 (-0.09%)
GSK : 40.69 (-0.68%)
Emisphere Development Update

Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type...

EMIS : 2.4000 (unch)
NVO : 49.81 (-0.82%)
New Education Initiative Will Promote Specialized Physician Training in Obesity Care Across the U.S.

FOR IMMEDIATE RELEASE: The Obesity Society and the Obesity Medicine Association announce the establishment of the Obesity Medicine Fellowship Development Program, a new collaborative effort to increase...

NVO : 49.81 (-0.82%)
Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3

Bagsvaerd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide...

NVO : 49.81 (-0.82%)
EyePoint Pharmaceuticals Appoints Goran Ando, M.D., to Board of Directors

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Goran Ando, M.D., to...

NVO : 49.81 (-0.82%)
EYPT : 2.48 (+16.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 50.17
1st Resistance Point 49.99
Last Price 49.81
1st Support Level 49.55
2nd Support Level 49.29

See More

52-Week High 58.37
Fibonacci 61.8% 51.75
Last Price 49.81
Fibonacci 50% 49.70
Fibonacci 38.2% 47.65
52-Week Low 41.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar